X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
USA (Orange Book)
Europe
0
Canada
Australia
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
1. Bms-986165
1. Bms-986165
2. 1609392-27-9
3. Tyk2-in-4
4. Bms986165
5. Deucravacitinib [usan]
6. N0a21n6rau
7. 6-(cyclopropanecarbonylamino)-4-[2-methoxy-3-(1-methyl-1,2,4-triazol-3-yl)anilino]-n-(trideuteriomethyl)pyridazine-3-carboxamide
8. Deucravacitinib (usan)
9. Sotyktu
10. Unii-n0a21n6rau
11. Deucravacitinib [inn]
12. Deucravacitinib [jan]
13. Chembl4435170
14. Deucravacitinib [who-dd]
15. Schembl20520348
16. Gtpl10432
17. Ex-a3154
18. Bdbm50507816
19. Mfcd31715455
20. Nsc825520
21. S8879
22. Tyk2-in-4(bms986165)
23. Who 11342
24. At18623
25. Nsc-825520
26. Compound 11 [pmid: 31318208}
27. Ncgc00687789-01
28. Ac-31543
29. Hy-117287
30. Cs-0065044
31. D11817
32. 3-pyridazinecarboxamide, 6-((cyclopropylcarbonyl)amino)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)-
33. 3-pyridazinecarboxamide, 6-((cyclopropylcarbonyl)amino]-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)n-(methyl-d3)-
34. 6-((cyclopropylcarbonyl)amino)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(2h3)methyl-3-pyridazine-carboxamide
35. 6-((cyclopropylcarbonyl)amino]-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-((2h3)methyl)pyridazine-3-carboxamide
36. 6-[(cyclopropylcarbonyl)amino]-4-[[2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl]amino]-n-(methyl-d3)-3-pyridazinecarboxamide
| Molecular Weight | 425.5 g/mol |
|---|---|
| Molecular Formula | C20H22N8O3 |
| XLogP3 | 1.2 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 7 |
| Exact Mass | 425.20031683 g/mol |
| Monoisotopic Mass | 425.20031683 g/mol |
| Topological Polar Surface Area | 136 Ų |
| Heavy Atom Count | 31 |
| Formal Charge | 0 |
| Complexity | 648 |
| Isotope Atom Count | 3 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Treatment of psoriasis
Treatment of Systemic Lupus Erythematosus (SLE)
Dermatologic Agents
Drugs used to treat or prevent skin disorders or for the routine care of skin. (See all compounds classified as Dermatologic Agents.)
Protein Kinase Inhibitors
Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)
L - Antineoplastic and immunomodulating agents
L04 - Immunosuppressants
L04A - Immunosuppressants
L04AA - Selective immunosuppressants
L04AA56 - Deucravacitinib
Market Place
